Zimmer Biomet Holdings Inc. (ZBH)

141.51
0.51 0.36
NYSE : Health Technology
Prev Close 142.02
Open 141.42
Day Low/High 140.24 / 142.49
52 Wk Low/High 96.99 / 143.56
Volume 448.29K
Avg Volume 1.19M
Exchange NYSE
Shares Outstanding 205.31M
Market Cap 28.67B
EPS -1.90
P/E Ratio N/A
Div & Yield 0.96 (0.69%)

Latest News

Zimmer Biomet Receives FDA Clearance Of JuggerStitch™ Meniscal Repair Device

Zimmer Biomet Receives FDA Clearance Of JuggerStitch™ Meniscal Repair Device

The Next Generation Of This Pioneering Meniscal Repair Technology

Zimmer Biomet Commences Commercial Release Of Persona® Revision Knee System

Zimmer Biomet Commences Commercial Release Of Persona® Revision Knee System

Revision System Completes the Persona Portfolio of Comprehensive and Personalized Knee Replacement Solutions

Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Zimmer Biomet Holdings, Inc. (ZBH)

Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Zimmer Biomet Holdings, Inc. (ZBH)

NEW YORK, Aug. 30, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zimmer Biomet Holdings, Inc.

Zimmer Biomet's Innovative Treatment For Young Patients With Scoliosis Receives FDA Approval

Zimmer Biomet's Innovative Treatment For Young Patients With Scoliosis Receives FDA Approval

The Tether™ represents the first approval order for a humanitarian use device in spinal pediatrics within the last 15 years

Zimmer Biomet Recommends Shareholders Reject Mini-Tender Offer By TRC Capital Corporation

Zimmer Biomet Recommends Shareholders Reject Mini-Tender Offer By TRC Capital Corporation

WARSAW, Ind., July 26, 2019 /PRNewswire/ -- Zimmer Biomet Holdings, Inc.

Zimmer Biomet Jumps on Second-Quarter Earnings Beat

Zimmer Biomet Jumps on Second-Quarter Earnings Beat

Shares of orthopedic device maker Zimmer Biomet jump after the company reports second-quarter earnings and sales that beat analysts' forecasts.

Zimmer Biomet Announces Second Quarter 2019 Financial Results

Zimmer Biomet Announces Second Quarter 2019 Financial Results

- Net sales of $1.989 billion for the second quarter represent a decrease of 0.9% from the prior year period; an increase of 1.2% on a constant currency basis

Lifshitz & Miller LLP Announces Investigation Of Array BioPharma Inc., C&J Energy Services, Inc., Liberty Expedia Holdings, Inc., And Raytheon Company, Shutterfly, Inc., Sotheby's And Stewardship Financial Corporation, And Zimmer Biomet Holdings, Inc.

Lifshitz & Miller LLP Announces Investigation Of Array BioPharma Inc., C&J Energy Services, Inc., Liberty Expedia Holdings, Inc., And Raytheon Company, Shutterfly, Inc., Sotheby's And Stewardship Financial Corporation, And Zimmer Biomet Holdings, Inc.

NEW YORK, June 27, 2019 /PRNewswire/ -- Array BioPharma Inc. (ARRY) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the proposed sale of ARRY to Pfizer, Inc.

Zimmer Biomet Announces Chief Financial Officer Transition Plan

Zimmer Biomet Announces Chief Financial Officer Transition Plan

Suketu Upadhyay Appointed Chief Financial Officer, Effective July 1, 2019, Succeeding Daniel Florin

Zimmer Biomet Holdings Announces Audio Webcast And Conference Call Of Second Quarter 2019 Results

Zimmer Biomet Holdings Announces Audio Webcast And Conference Call Of Second Quarter 2019 Results

WARSAW, Ind., June 17, 2019 /PRNewswire/ -- Zimmer Biomet Holdings, Inc.

Zimmer Biomet Announces Quarterly Dividend For Second Quarter Of 2019

Zimmer Biomet Announces Quarterly Dividend For Second Quarter Of 2019

WARSAW, Ind., June 11, 2019 /PRNewswire/ -- Zimmer Biomet Holdings, Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AINV, RGLD, SAFM Downgrades: ENR, EVK, GMLP, HTHT, PLAB, ZBH Initiations: AMRX, AQB Read on to get TheStreet Quant Ratings' detailed report:

ZBH INVESTOR ALERT: ROSEN, TOP RANKED LAW FIRM, Announces Investigation Of Breaches Of Fiduciary Duties By Management Of Zimmer Biomet Holdings, Inc. - ZBH

ZBH INVESTOR ALERT: ROSEN, TOP RANKED LAW FIRM, Announces Investigation Of Breaches Of Fiduciary Duties By Management Of Zimmer Biomet Holdings, Inc. - ZBH

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential breaches of fiduciary duties by management of Zimmer Biomet Holdings, Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AIMC, BEN, EMX, FBM, HHC, IMAX, JYNT, LAUR, PXD, RRR, VIAB, VRTS, ZBH Downgrades: CLFD, CNSL, CVA, CZWI, LOGM, NR, USAK Initiations: AIHS Read on to get TheStreet Quant Ratings' detailed report:

Zimmer Biomet Announces First Quarter 2019 Financial Results

Zimmer Biomet Announces First Quarter 2019 Financial Results

- Net sales of $1.976 billion for the first quarter represent a decrease of 2.1% from the prior year period, an increase of 0.7% on a constant currency basis

Zimmer Biomet To Present At Bank Of America Merrill Lynch Healthcare Conference

Zimmer Biomet To Present At Bank Of America Merrill Lynch Healthcare Conference

WARSAW, Ind., April 23, 2019 /PRNewswire/ -- Zimmer Biomet Holdings, Inc.

Playbook for the Fed: Cramer's 'Mad Money' Recap (Thursday 3/21/19)

Playbook for the Fed: Cramer's 'Mad Money' Recap (Thursday 3/21/19)

Jim Cramer has a playbook for finding the stocks that can make money without the economy filling the sails.

Berkshire Hathaway, Callaway Golf, Microsoft: 'Mad Money' Lightning Round

Berkshire Hathaway, Callaway Golf, Microsoft: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Berkshire Hathaway, Callaway Golf, Whitestone, Microsoft, Centene and more.

How to Fatten Up Your Portfolio By Investing in the Obesity Epidemic

How to Fatten Up Your Portfolio By Investing in the Obesity Epidemic

As the U.S. and the world grow fatter, some investors are seeing green as they bulk up on stocks of companies on the front-lines of this 21st century Battle of the Bulge.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABEV, DGII, FLWS, JVA, LBRDA, MUR, OLP, RDY, SGEN, TESS, TWIN, VMC, YRCW Downgrades: CRUS, MINI, USLM, ZBH Initiations: CBTX, MBIN, SOGO Read on to get TheStreet Quant Ratings' detailed report:

IDEXX Labs, Evolent Health, Triton: 'Mad Money' Lightning Round

IDEXX Labs, Evolent Health, Triton: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at IDEXX Labs, Evolent Health, Triton, Western Gas Partners, Zimmer Biomet and more.

When Sellers Walk Away: Cramer's 'Mad Money' Recap (Tuesday 7/31/18)

When Sellers Walk Away: Cramer's 'Mad Money' Recap (Tuesday 7/31/18)

Jim Cramer says the tide of selling eventually ebbs, and when it does, stocks rally.

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Straying from these names could land you in quicksand as the 4th quarter begins.

Jim Cramer: Valuations Now Have No Relation to Common Sense

Jim Cramer: Valuations Now Have No Relation to Common Sense

Analyst downgrades and mind-boggling P/E ratios do not matter in this current market.

TheStreet Quant Rating: C+ (Hold)